Follow the Pundits

Tag: Paulson & Co

Editorial illustration depicting the world's leading hedge fund strategies in 2026, including quantitative investing, activist investing, global market analysis, risk management, and data-driven portfolio management.

Best Hedge Funds 2026: Top Quants, Activists, and High-Return Managers

This article lists some of the most successful hedge funds based on the quality of their management, track record, key strategic focus, risk management, fee structure, and other criteria. Hedge funds follow various strategies to offer investors a compelling, but risky investment alternative. Investing with one requires a high minimum investment and specific wealth profile (high net worth, high-income generation threshold) from accredited investors. Hedge funds charge (approx.) a 2% management and 20% performance fee. The idea or hope is that they are worth it. 

Read entire article

Tags: Abrams Capital Management, Appaloosa Management, AQR Capital, Ark Invest, Baillie Gifford, Baker Bros., Baker Bros. Advisors, Balyasny Asset Management, Berkshire Hathaway, best hedge funds, bridgewater, Bridgewater Associates, Citadel, citadel llc, Coatue Management, D.E. Shaw, D.E. Shaw & Co., Davidson Kempner, Elliott Investment Management, featured-home, Fisher Investments, Greenlight Capital, hedge fund managers, hedge fund strategies, hedge funds, Himalaya Capital, hub-hedge, institutional investing, investment philosophy, long short investing, Millennium, Millennium Management, Paulson & Co., Pershing Square, portfolio analysis, portfolio management, quantitative investing, Renaissance, Renaissance Technologies, The Baupost Group, The Best Hedge Funds, The Top Hedge Funds, Third Point, Tiger Global, top hedge funds, Two Sigma, value investing, ValueAct Capital, Viking Global Investors
Futuristic medical-pharma cityscape with glowing capsules, rising stock arrows, and a giant magnifying glass over Bausch Health, symbolizing deep-value investing and insider buying.

Paulson & Co Keeps Adding to His Bausch Health Stake: Should Investors See Eye to Eye With Him?

Billionaire John Paulson now owns nearly 19% of Bausch Health — and he keeps buying. With improving earnings, low valuation, and high risk, BHC may be a speculative value play worth watching.

Read entire article

Tags: Bausch Health, BHC Stock, Buy or sell BHC, contrarian investing, Contrarian Investment, ContrarianStocks, Debt Risk, featured-hedge-funds, featured-overseas, Funanc1al Edge, FUNanc1al Health Hub, Funanc1al Humor, FUNanc1al Investing, FUNanc1al Stocks & Fun, hub-insiders, Insider Buying, John Paulson, Paulson & Co, Pharma Stocks, Risks Investing in BHC, Turnaround Stories, Value Stocks, Why Buy BHC
Digital illustration of John Paulson standing atop a golden minecart loaded with gold bars and antimony atoms, surrounded by pine trees and American flags. Idaho mountains rise in the background. Caption: “Paulson’s Gold Rush?”

John Paulson Is Loading Up on Perpetua Resources. Should You?

John Paulson knows a good discount when he sees one—and he just grabbed another $100M worth of Perpetua Resources (PPTA). But what is this gold-and-antimony play really about? From Idaho mines to strategic minerals and a wink at squirrel invasions, we break it all down.

Read entire article

Tags: Antimony, Antimony Mining, best hedge funds, CriticalMinerals, Funanc1al, Funanc1al Edge, Funanc1al for Investors, Funanc1al Insider Series, Funanc1al Investing, Funanc1alEdge, Funanc1alHumor, Funanc1alInsiderSeries, Funanc1alInvesting, Funanc1alStocks, Gold Mining, GoldStocks, IdahoInvesting, insider buying, Insider Buys, Insider Purchases, InsiderActivity, InsiderBuy, InsiderBuying, InsiderBuys, InsiderPurchases, InsiderWatch, Investment Diversification, John Paulson, JohnPaulson, MiningStocks, Paulson & Co, PerpetuaResources, PPTA, PPTA Stock, SpeculativePlays, WatchlistWorthy